Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT05047510
Recruiting Not applicable

GPC3 Targeted Fluorescence Image Guided Surgery of Hepatocellular Carcinoma

NCT05047510 · tracked via the Priya Life Science China tracker
Sponsor
Chinese Academy of Sciences
Phase
Not applicable
Started
2021-09-10
Last updated
2023-08-30

Condition(s) studied

Hepatocellular Carcinoma

Investigational drug(s) / intervention(s)

Anti-GPC3-IRDye800CW

Anti-GPC3-IRDye800CW: Drug Injection: Anti-GPC3-IRDye800CW

Study summary

This study is to evaluate whether intraoperative fluorescence imaging targeting GPC3 can aid improve the surgical accuracy of hepatocellular carcinoma.

The main purposes of this study include:

① To raise the detection rate of hepatocellular carcinoma intraoperatively using the novel NIR-II fluorescence molecular imaging and the GPC-3 targeted fluorophore.

② To validate the safety and effectiveness of the designed GPC-3 targeted fluorophore for clinical application.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Patients who have been diagnosed with hepatocellular carcinoma. 2. Planned to receive hepatectomy. 3. Liver function Child-Pugh A/B. 4. GPC-3 was validated highly expressed preoperatively. 5. Aged 18 to 75, and the expected lifetime is longer than 6 months. 6. Approved to sign the informed consent. Exclusion Criteria: 1. Allergic to IRDye800. 2. Enrolled in other trials in the past 3 months. 3. Another malignant tumor was found. 4. Undesirable function of heart, lung, kidney, or any other organs. 5. Unable to tolerate a hepatectomy. 6. The researchers considered inappropriate to be included.

Primary outcome measure(s)

  • HCC lesions — During hepatocellular resection surgery.
    Numbers of intraoperatively detected hepatocellular carcinoma lesions.

Trial sites (2)

FacilityCityRegionStatus
Zhuhai People's Hospital Zhuhai Guangdong Recruiting
The Affiliated Hospital of Southwest Medical University Luzhou Sichuan Recruiting

More Chinese Academy of Sciences trials in China

Prospective Collection and Registry Study of Multicenter, Multidisciplinary Surgical Minimally Invasive Videos Starting soon
AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy Recruiting
Research on Identifying Critical Surgical Anatomy in Cholecystectomy Videos Based on Deep Learning Recruiting
Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics Recruiting
Quality Control of Ultrasound Images During Early Pregnancy Via AI Recruiting

Other trials for the same condition

A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC) Active, not recruiting
Deep Learning-Based Multidimensional Body Composition Mapping for Outcome Prediction in HCC Patients Undergoing TACE Recruiting
HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）Plus Sintilimab and Donafenib in the First-line Treatment of Unresectable Hepatocellular Carcinoma Recruiting
Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma Recruiting
A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05047510 on ClinicalTrials.gov ↗ ← All trials in China